Pfizer Inc

詳細情報 Pfizer Inc 企業名

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

企業情報

企業コードPFE

会社名Pfizer Inc

上場日Jan 17, 1944

設立日1942

最高経営責任者「CEO」Dr. Albert Bourla, Ph.D.

従業員数81000

証券種類Ordinary Share

決算期末Jan 17

本社所在地66 Hudson Boulevard East

都市NEW YORK

証券取引所NYSE Consolidated

国United States of America

郵便番号10001-2192

電話番号12127332323

ウェブサイトhttps://www.pfizer.com/

企業コードPFE

上場日Jan 17, 1944

設立日1942

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+10.54%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+8.26%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+149.67%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

--

Mr. Aamir Malik

Executive Vice President, Chief US Commercial Officer

29.55K

+7.80K%

Ms. Payal Sahni

Executive Vice President, Chief People Experience Officer

24.85K

+6.62%

Mr. Cyrus Taraporevala

Independent Director

10.00K

--

Dr. Scott Gottlieb, M.D.

Independent Director

10.00K

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+10.54%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+8.26%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+149.67%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

Eliquis alliance revenues and direct sales

1.92B

14.02%

Prevnar family

1.66B

12.10%

Vyndaqel family

1.49B

10.83%

All other Hospital

1.16B

8.42%

Oncology-Ibrance

977.00M

7.12%

Other

6.51B

47.50%

地域別USD

会社名

収益

比率

United States

8.37B

61.06%

Developed Markets

3.18B

23.17%

Emerging Markets

2.16B

15.77%

事業別

地域別

事業別USD

会社名

収益

比率

Eliquis alliance revenues and direct sales

1.92B

14.02%

Prevnar family

1.66B

12.10%

Vyndaqel family

1.49B

10.83%

All other Hospital

1.16B

8.42%

Oncology-Ibrance

977.00M

7.12%

Other

6.51B

47.50%

株主

更新時刻: Thu, May 15

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.16%

State Street Global Advisors (US)

5.22%

BlackRock Institutional Trust Company, N.A.

5.13%

Geode Capital Management, L.L.C.

2.21%

Wellington Management Company, LLP

1.82%

Other

76.46%

株主統計

比率

The Vanguard Group, Inc.

9.16%

State Street Global Advisors (US)

5.22%

BlackRock Institutional Trust Company, N.A.

5.13%

Geode Capital Management, L.L.C.

2.21%

Wellington Management Company, LLP

1.82%

Other

76.46%

種類

株主統計

比率

Investment Advisor/Hedge Fund

31.97%

Investment Advisor

24.02%

Research Firm

3.43%

Pension Fund

2.09%

Bank and Trust

1.84%

Sovereign Wealth Fund

1.65%

Hedge Fund

1.28%

Insurance Company

1.25%

Private Equity

0.07%

Other

32.40%

機関投資家保有株

更新時刻: Tue, Jul 1

比率

保有株式数

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

4907

3.85B

67.70%

-61.24M

2025Q1

5074

3.86B

67.90%

-51.97M

2024Q4

5153

3.84B

67.74%

-83.26M

2024Q3

5005

3.85B

67.99%

-51.77M

2024Q2

5026

3.84B

67.75%

-120.77M

2024Q1

5032

3.89B

68.71%

-120.39M

2023Q4

5089

3.97B

70.25%

-96.67M

2023Q3

4952

4.00B

70.89%

-71.80M

2023Q2

4962

4.02B

71.16%

-62.35M

2023Q1

4947

4.02B

71.28%

-30.98M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

520.58M

9.16%

+4.61M

+0.89%

Mar 31, 2025

State Street Global Advisors (US)

296.97M

5.22%

+6.49M

+2.23%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

291.55M

5.13%

+12.00M

+4.29%

Mar 31, 2025

Geode Capital Management, L.L.C.

125.65M

2.21%

+5.06M

+4.20%

Mar 31, 2025

Wellington Management Company, LLP

103.49M

1.82%

-36.50M

-26.07%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

87.79M

1.54%

+3.82M

+4.55%

Dec 31, 2024

MFS Investment Management

73.03M

1.28%

-1.19M

-1.60%

Mar 31, 2025

State Farm Insurance Companies

57.75M

1.02%

+493.70K

+0.86%

Mar 31, 2025

BlackRock Asset Management Ireland Limited

50.47M

0.89%

+4.52M

+9.83%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

48.03M

0.84%

-107.43M

-69.10%

Mar 31, 2025

詳細を見る

関連ETF

更新時刻: Sun, Jul 6

銘柄名

比率

First Trust NASDAQ Pharmaceuticals ETF

7.19%

First Trust Morningstar Dividend Leaders Index Fund

6.42%

NYLI Healthy Hearts ETF

4.84%

Invesco Pharmaceuticals ETF

4.81%

WBI Power Factor High Dividend ETF

4.74%

Vaneck Durable High Dividend ETF

4.54%

iShares U.S. Pharmaceuticals ETF

4.53%

VanEck Morningstar Wide Moat Value ETF

4.4%

VanEck Pharmaceutical ETF

4.3%

Amplify Weight Loss Drug & Treatment ETF

3.98%

詳細を見る

First Trust NASDAQ Pharmaceuticals ETF

比率7.19%

First Trust Morningstar Dividend Leaders Index Fund

比率6.42%

NYLI Healthy Hearts ETF

比率4.84%

Invesco Pharmaceuticals ETF

比率4.81%

WBI Power Factor High Dividend ETF

比率4.74%

Vaneck Durable High Dividend ETF

比率4.54%

iShares U.S. Pharmaceuticals ETF

比率4.53%

VanEck Morningstar Wide Moat Value ETF

比率4.4%

VanEck Pharmaceutical ETF

比率4.3%

Amplify Weight Loss Drug & Treatment ETF

比率3.98%

配当金

過去5年間の配当金総支払額は 44.91B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Dec 12, 2024

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025

Jan 24, 2025

Mar 07, 2025

Jan 24, 2025

Oct 09, 2024

PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024

Nov 08, 2024

Dec 02, 2024

Nov 08, 2024

Jun 26, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024

Jul 26, 2024

Sep 03, 2024

Jul 26, 2024

Apr 24, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024

May 10, 2024

Jun 14, 2024

May 09, 2024

Dec 14, 2023

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024

Jan 26, 2024

Mar 01, 2024

Jan 25, 2024

Oct 04, 2023

PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Dec 04, 2023

Nov 09, 2023

Jun 22, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023

Jul 28, 2023

Sep 05, 2023

Jul 27, 2023

Apr 26, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023

May 12, 2023

Jun 09, 2023

May 11, 2023

Dec 09, 2022

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023

Jan 27, 2023

Mar 03, 2023

Jan 26, 2023

Sep 22, 2022

PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022

Nov 04, 2022

Dec 05, 2022

Nov 03, 2022

詳細を見る

株式分割

日付

種類

比率

データなし

日付

種類

比率

データなし

25.560USD

Pfizer Inc

25.560

概要

企業名

金融